Skinbiotherapeutics Share Discussion Threads

[loungeact] 09/11/2017 14:15

Bobalot - Firstly, please don't shout. "OPTI is making loads of progress and so is SkinBio -- microbiome platforms are going to change the way we view treatments." - I think this is more an opinion than a 'fact or article', and an opinion that I actually agree with. Perhaps I shouldn't have suggested you were ramping as that makes it sounds like you're making stuff up, which I know you're not. I just think it's a little off putting when you see one poster flooding the board. You're invested and you want to the share price to rise, I get that, we all do, maybe just chill a out a bit though. Anyway, I've said my bit, each to their own.

[deeppockets] 09/11/2017 14:02

I can't remember the actual phrase the CEO used in the interview but it sounded like they are progressing discussions with potential partners at the same time as going through the trials so that once they have passed all the necessary regulatory issues they are good to go rather than then starting discussions at that stage. I seem to remember in the early stage they talked about an anti ageing cream as the product was shown to "tighten" skin cells but that seems to have gone quiet.

[bobalot] 09/11/2017 13:54

RUBBISH -- STATING FACTS BACKED UP WITH ARTICLES.

[loungeact] 09/11/2017 13:29

Bobalot, I feel like your ramping is going to put people off from reading, adding to this thread. You're flooding the board. I'm excited too, but calm it down a little.

[bobalot] 09/11/2017 12:56

OPTI is making loads of progress and so is SkinBio -- microbiome platforms are going to change the way we view treatments.

[bobalot] 09/11/2017 12:52

This was a very interesting comment from the company:

Human trials

Earlier this week SkinBioTherapeutics said it expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.

SkinBio looking confident to close a commercial deal.

[bobalot] 09/11/2017 11:16

TT an excellent prognosis -- compliance coming...with a major hike in the share price

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

NOTE: after human trials the Registration process becomes the responsibility of the commercial partner..thus commercialisation starts after a month long human trial in Q2/18 along with commercialisation once proved viable.

[trotterstrading] 09/11/2017 11:09

Elrico, while not a complete no brainer it's quite close IMHO. Bear in mind the treatment has now been tested for safety and efficacy on live skin, albeit cultured in the lab. In addition we now have independent confirmation of excellent toxicity profile. Repeat these results in patient trials next year and it's game, set, match SBTX and Shareholders;0)

[bobalot] 09/11/2017 10:53

SkinBioTherapeutics technology gets double green light - next stop human studies
Share ---- 07:33 09 Nov 2017

Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells)

The company's first product will be a skincare cosmetic

SkinBioTherapeutics PLC (LON:SBTX) said its SkinBiotix technology has passed two additional and final toxicity tests, meaning it is safe to use in the company’s three target markets.

Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells).

Prior to that, SkinBiotix was found not to be cytotoxic, which in layman’s terms meant it didn’t kill cells it came in contact with.

Focusing on efficacy
#
"Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focusing on further proving its efficacy,” said Dr Catherine O'Neill, chief executive of SkinBioTherapeutics.

The company is focused on developing products and treatments that effect the portion of the human microbiome that resides on the skin.

This is a mix of bacteria, yeasts, and parasites that live on the body’s biggest organ.  Sounds gross, but this microbial ecosystem is thought to be key to skin health.

Based on the work of CEO O’Neill at Manchester University, the SkinBiotix platform is protected by three patent families and 18 patent applications.

It is also supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

As mentioned above, the firm is developing three products that manage, protect and restore the body’s outer layer.

First cab off the rank

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

Human trials

Earlier this week SkinBioTherapeutics said it expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.

Tentative discussions have already begun, said CEO O’Neill, but human data is crucial to the process. 

In the release Thursday, the company said it was confident of human studies getting underway next year.

www.proactiveinvestors.co.uk/companies/news/186987/skinbiotherapeutics-technology-gets-double-green-light-next-stop-human-studies-186987.html

[elrico] 09/11/2017 10:49

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:

"Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focussing on further proving its efficacy.

"With this news today, the technology has passed the three necessary toxicity tests showing that it can be safely applicable across our three target markets.

"We are continuing formulation development and are confident about starting our human studies in 2018."

....
Keep tucking SBTX away - NO BRAINER AFTER successful human studies, not before.

[bobalot] 09/11/2017 10:33

After passing those safety tests --- clinical human trials will be easy...it is set to pass that as well...WARREN is right SkinBio is now a NO BRAINER....STRONG BUY imo.

[warren1982] 09/11/2017 09:23

I just keep adding when funds allow,OPTI'S baby is starting to grow, this is a no brainer.

[shrewdmole] 09/11/2017 08:39

Raf

It's definitely one to tuck away.

Just one application and this is a 10 bagger easily.

Top quality and well reapected CEO in here field. That's why I believe they are already talking to partners.

S

[rafboy] 09/11/2017 08:27

I think people are underestimating how large SBTX could become and are waiting to buy in. The proposed application areas are all significant and next year could well see products being released soon after the human studies complete. I believe now is the time to be building a position in SBTX. Just my personal view.

[parob] 09/11/2017 07:17

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:"Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focussing on further proving its efficacy."With this news today, the technology has passed the three necessary toxicity tests showing that it can be safely applicable across our three target markets."We are continuing formulation development and are confident about starting our human studies in 2018."

[opodio] 09/11/2017 07:13

SBTX news means nothing

10 years away from revenues

[loungeact] 08/11/2017 17:52

Manchester, UK - 8 November 2017 - SkinBioTherapeutics (AIM: SBTX), a life science company focused on skin health, is pleased to announces that Dr Catherine O'Neill, CEO, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd.

The event will be held on Monday 4th December in Mayfair, London W1 and will commence at 5pm.

To register your interest, please email [e-mail] or call 0203 621 4121.

[bobalot] 08/11/2017 14:26

Here's another sound bite from Doc Cath; she is now sounding very upbeat:

“Once the results [from the human study] are in we are good to go.”

Skinbiotex might be either an ingredient in someone else’s product or a brand in its own right.

O’Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report.

She said was delighted to receive the award especially as Skinbiotherapeutics was listed in the great science category.

“SkiBiotherapeutics is founded on very robust science and is proud of its scientific heritage.”

[onedayrodders] 08/11/2017 12:47

I hear ya !

[elrico] 08/11/2017 12:17

Thanks for that ODR - I don't feel so odd now, or guilty ;)

Seriously though...It's expensive being a woman. Imagine the margins on royalties -
Kching.

[onedayrodders] 08/11/2017 10:41

very true elrico

I often use some of the wife's when she's not looking

[bobalot] 08/11/2017 08:49

What Dr. Cath said recently is very promising imo...this will take off soon just like OPTI did after its ipo.

SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.

Tentative discussions have already begun, Cath O’Neill, the skin microbiome specialist’s chief executive told Proactive Investors, but human data is crucial to the process.  

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

[bobalot] 08/11/2017 08:48

Its on another break out like yesterday...excellent.